Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor

Executive Summary

FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway

You may also be interested in...



Crestor Patent Battle Could Have Ripple Effect: Is A Salt Equivalent To Base Compound?

Watson filed a 505(b)(2) NDA for a zinc salt of AstraZeneca’s Crestor, which AstraZeneca claims infringes its patent; if Watson prevails more generic manufacturers may pursue this pathway around a patent.

505(b)(2) Standards Needed To Ensure Predictability – Pfizer Attorney

FDA should develop standards for use of the 505(b)(2) approval pathway to better allow for predictability of its application, according to Pfizer Assistant General Council Jeffrey Chasnow

505(b)(2) Standards Needed To Ensure Predictability – Pfizer Attorney

FDA should develop standards for use of the 505(b)(2) approval pathway to better allow for predictability of its application, according to Pfizer Assistant General Council Jeffrey Chasnow

Related Content

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel